

Advancing the Pipeline on Key Programs

	<i>Estimated timelines</i>	1H'19	2H'19	2020
CNS	Ubrogепant (Acute treatment of migraine)	NDA filed in Q1	PDUFA: Dec 2019	LAUNCH
	Atogepant (Prevention of migraine)	Phase 3 initiated in chronic migraine		Phase 3 results in episodic migraine
	Cariprazine (Bipolar Depression)	PDUFA: May 2019	LAUNCH	
	Rapastinel (MDD/Suicidalіty)		Interim analysis of suicidalіty and monotherapy studies	
	AGN-241751 (MDD)		Phase 2 topline results	
EYE	Abicipar (AMD/DME)	Regulatory submission with FDA in 1H'19; Maple study results 1H'19		LAUNCH in AMD; Phase 3 initiation in DME
	Brimonidine DDS (Geographic Atrophy)		Initiation of Phase 3 studies	
	Bimatoprost SR (Glaucoma)	Regulatory submission with FDA		LAUNCH
	Presbysol (Presbyopia)	Phase 3 ongoing		Phase 3 topline results
GI	CVC (NASH)	Phase 2 combination ongoing (CVC/Tropifexor)		Phase 3 topline results (CVC)
	Relamorelin (Gastroparesis)	Phase 3 studies (pivotal and long-term safety) ongoing		Phase 3 topline results
	Brazikumab (CD/UC)	Phase 2b/3 ongoing (CD); Phase 2 ongoing (UC)		1 st Stage of Phase 2b/3 topline results (CD)
MA	CoolSculpting (CoolTone™)		LAUNCH	
	Botox (Masseter)	Initiation of Phase 2b studies (US/EU)	Initiation of Phase 3 studies (Asia/Canada)	
	Fillers (Voluma, Volite)	LAUNCH VOLUX (ex-US)		LAUNCH VOLUMA Chin (US)